We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
15 Oct 19
Roche’s MabThera/Rituxan has secured the FDA approval in June 2018 and the European Commission approval in March 2019
14 Oct 19
JADE MONO-1 is a 12-week, double-blind, randomised parallel group study to evaluate abrocitinib 200mg, abrocitinib 100mg, or placebo
11 Oct 19
The FINCH Phase III programme has been designed to investigate the efficacy and safety of filgotinib, in early-stage…
10 Oct 19
The lebrikizumab Phase 3 study programme is designed to confirm the safety and efficacy of lebrikizumab in treating…
03 Oct 19
PREVENT study showed a sustained response and consistent safety profile with previous clinical trials and no new safety…
01 Oct 19
The results showed significant improvements in overall survival (OS) and objective response rates (ORR) for the BRAFTOVI Triplet…
20 Sep 19
Contezolid was associated with fewer drug-related hematologic laboratory adverse events
16 Sep 19
The FDA has granted Fast Track designation to abexinostat, in combination with pazopanib, as a first- or second-line…
11 Sep 19
OCREVUS is a humanised monoclonal antibody designed to target CD20-positive B cells, a specific type of immune cell…
10 Sep 19
Pfizer enrolled subjects for the Phase 3 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate for the prevention…